Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Anti-Cancer Agents in Medicinal Chemistry|May 16, 2009
Tripentones: a promising series of potent anti-cancer agentsChristophe Rochais, Patrick Dallemagne, Sylvain Rault
Medicinal Research Reviews|August 24, 2024
Indirect influence on the BDNF/TrkB receptor signaling pathway via GPCRs, an emerging strategy in the treatment of neurodegenerative disordersMirjana Antonijevic, Patrick Dallemagne, Christophe Rochais
Current Medicinal Chemistry|October 14, 2010
Intramolecular cyclisation of β-aryl-β-amino acids in the design of novel heterocyclic systems with therapeutic interest: an unfailing source of diversityChristophe Rochais, Sylvain Rault, Patrick Dallemagne
Molecules (Basel, Switzerland)|January 21, 2023
C3-Symmetric Ligands in Drug Design: When the Target Controls the Aesthetics of the DrugMirjana Antonijevic, Christophe Rochais, Patrick Dallemagne
European Journal of Medicinal Chemistry|October 4, 2019
Structure-activity relationships of serotonin 5-HT<sub>7</sub> receptors ligands: A reviewSangeetha-Laura Thirumaran, Alban Lepailleur, Christophe Rochais
European Journal of Medicinal Chemistry|January 23, 2025
Analysis of skeletal diversity of multi-target directed ligands (MTDLs) targeting Alzheimer's diseaseUzma Azam, Muhammad Moazzam Naseer, Christophe Rochais
Pharmaceuticals (Basel, Switzerland)|May 19, 2019
26th Annual GP2A Medicinal Chemistry Conference & 32nd Journées Franco-Belges de PharmacochimiePatrick Dallemagne, Christophe Rochais, Pascal Marchand, et al.
Future Medicinal Chemistry|May 9, 2024
Synthesis and interest in medicinal chemistry of β-phenylalanine derivatives (β-PAD): an update (2010-2022)Chloé Rémondin, Serge Mignani, Christophe Rochais, et al.
The Journal of Pharmacy and Pharmacology|June 7, 2025
Targeting together cholinesterases and serotonin reuptake against Alzheimer's diseaseThomas Guiselin, Cédric Lecoutey, Christophe Rochais, et al.
Archiv Der Pharmazie|April 2, 2025
Implication of Central β<sub>2</sub> Adrenergic Receptor for the Development of Novel Drugs Against Alzheimer's DiseaseAlice Wang, Marc Since, Patrick Dallemagne, et al.
Pageof 7